23948sdkhjf
Logga in eller skapa en prenumeration för att spara artiklar
Få tillgång till allt innehåll på Life Science Sweden
Ingen bindningstid eller kortinformation krävs
Gäller endast personlig prenumeration.
Kontakta oss för en företagslösning.
Annons
Annons
Innehållet nedan modereras inte i förväg och omfattas därmed inte av webbplatsens utgivningsbevis.
Dela sida
Sponsrat innehåll

Supporting Investigator Initiated Clinical Studies—From Start to Finish

Many important clinical studies start with researchers – not pharmaceutical companies. In investigator initiated studies, pharmaceutical companies often support only parts of the study. Sponsorship typically sits with a university hospital and a responsible investigator, while the pharmaceutical company contributes through e.g. grants, study drugs, or logistical support.

In practice, this setup can be challenging. Research teams may lack the operational infrastructure or time needed to run the study efficiently and in accordance with regulatory requirements.

This is where Aurevia can make a real difference.

We have extensive experience supporting investigator‑initiated clinical studies with various activities, including:

  • Contracts with participating study sites
  • Regulatory applications (EC, CTIS)
  • Study documentation prior to study start (protocols, patient information, etc.)
  • Start‑up meetings
  • Monitoring
  • TMF management

Our clinical experience, flexibility, and strong local presence enable us to deliver support that keeps studies moving forward. We know how important investigator‑initiated studies are for clinical research—and we’re committed to getting them all the way over the finish line.

Get in touch if you’d like to learn more or need support with an upcoming clinical study.

Aurevia
Box 150 27
750 15 Uppsala
Uppsala kommun
Sverige
VAT nummer: SE5565873147

Kontaktperson

Ulrika Heldestad
BD & Sales Director, CRO
ulrika.heldestad@aurevia.com
Annons Annons
BREAKING
{{ article.headline }}
0.093|